Open-label Extension for Phase 3 Clinical Trials of Simufilam
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05575076 |
Recruitment Status :
Enrolling by invitation
First Posted : October 12, 2022
Last Update Posted : April 25, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer Disease | Drug: Simufilam | Phase 3 |
This is a multi-national, multi-center, fixed-dose, 52-week, open-label extension study. After completing participation in either RETHINK-ALZ (PTI-125-06) or REFOCUS-ALZ (PTI-125-07), subjects will have the option to participate in this study. After the subject provides consent and the Investigator confirms the subject satisfies both inclusion and exclusion criteria, the study drug will be administered at the research site on Study Day 1 and subsequent visits will be scheduled.
We anticipate up to 1600 subjects may enroll in this study. Approximately up to 150 clinical sites in the USA, Canada, South Korea, and Australia will have the option to participate in this collaborative research effort.
For subjects electing to participate, the clinical and laboratory assessments from the Week 76 (REFOCUS-ALZ) or Week 52 (RETHINK-ALZ) End-of-Treatment visit will serve as Baseline Visit assessments for the open-label study on Study Day 1. All subjects will return in 4 weeks and every 12 weeks thereafter for safety assessments. At all post-baseline visits, subjects will report any adverse events since their last visit. In addition to adverse event monitoring, safety will be evaluated at every visit by vital signs, brief examinations, clinical laboratory tests (biochemistry, hematology, and urinalysis) and the Columbia Suicide Severity Rating Scale (C-SSRS). Study drug use since the last visit will be assessed and a new bottle of study drug will be dispensed.
The emerging subject safety assessments will be monitored throughout the study by an independent Data Safety Monitoring Board (DSMB).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1600 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Open-label extension |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 mg Tablets in Participants With Mild to Moderate Alzheimer's Disease |
Actual Study Start Date : | November 7, 2022 |
Estimated Primary Completion Date : | July 15, 2026 |
Estimated Study Completion Date : | July 15, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Simufilam 100 mg
simufilam 100 mg oral tablet, twice daily
|
Drug: Simufilam
simufilam 100 mg oral tablet, twice daily
Other Name: PTI-125 |
- Adverse event monitoring [ Time Frame: Baseline to 52 weeks ]Adverse event monitoring
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 51 Years to 89 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criterion:
- Completed RETHINK-ALZ (PTI-125-07) or REFOCUS-ALZ (PTI-125-06).
- Clinical presentation continues to be consistent with Alzheimer's disease.
- Availability of a study partner.
Exclusion Criteria:
- Residence in a skilled nursing facility requiring 24-hour care.
- Evidence of a neurologic condition other than AD that significantly contributes to the subject's dementia.
- Current clinically significant psychiatric diagnosis other than AD.
- Unstable, clinically significant medical condition other than AD.
- Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05575076
Study Director: | Jim Kupiec, MD | Cassava Sciences, Inc. |
Responsible Party: | Cassava Sciences, Inc. |
ClinicalTrials.gov Identifier: | NCT05575076 |
Other Study ID Numbers: |
PTI-125-10 |
First Posted: | October 12, 2022 Key Record Dates |
Last Update Posted: | April 25, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |